The outlook is not very positive for Ranbaxy: Jigar Shah

Jigar Shah, Sr. VP & Head of Research, Kimeng Securities India Pvt. Ltd.

One word on Ranbaxy post the 488 crores that the company has posted today....

One will have to get into the full details of the profit number because there is a lot of foreign exchange element. The US FDA issues are unresolved, so that the price reflects most of the improvement that has taken place compared to past and the stock continues to be expensive, so I am not particularly positive. If the stock rises, it makes a good sense to take profit.